At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 114 enrolled
Drug / intervention
Drug: CD07805/47 gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea
In Brief
A Phase 3 clinical trial evaluating Drug: CD07805/47 gel and CD07805/47 gel Placebo for Rosacea. Completed, enrolled 114 participants across 7 sites in 3 countries.
Detailed Summary
Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesFrance, Russia, Sweden
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedFeb 2013
Primary CompletionOct 2013
TodayJul 2026
First PostedFeb 12, 2013
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.4 years ago
Interventions
Drug: CD07805/47 geldrug
CD07805/47 gel Placebodrug